Clinical Trials Search Results

A study to evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of OP-101 (dendrimer n-acetyl-cysteine) in Patients with Severe COVID-19.

Pooled Phase 3 (Cohort 1) and Phase 2 (Cohort 1A) To evaluate the virologic efficacy of REGN10933+REGN10987 compared to placebo in reducing viral load of SARS-CoV-2 To evaluate the clinical efficacy of REGN10933+REGN10987 compared to placebo, as measured by death or mechanical ventilation Phase 1/2 (Cohort 1) To exclude futility of REGN10933+REGN10987 compared to placebo, as measured by death or mechanical ventilation To evaluate the safety and tolerability of REGN10933+REGN10987 compared to placebo

A study to research the experimental drugs REGN10933 and REGN10987, given together as a treatment for people with COVID-19. The study is focused on people who have COVID-19 but do not need to be in the hospital.

This is a prospective multicenter study conducted to evaluate the performance of the LumiraDx SARS-CoV-2 Ag Ultra test in detecting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and LumiraDx SARS-CoV-2 & Flu A/B test in differential detection of SARS-CoV-2, Influenza A (Flu A) and Influenza B (Flu B) at point of care sites. Subjects presenting with symptoms suggestive of coronavirus disease 2019 (COVID-19) and/or Influenza at the time of the study visit will be enrolled and asked to donate swab sample(s) for testing in the device(s) under evaluation.

To compare the efficacy of nirmatrelvir (PF-07321332)/ritonavir to placebo for the treatment of symptomatic COVID-19 in non- hospitalized pediatric participants with COVID-19 who are at risk of progression to severe disease. Patients are randomized 1:1 and will receive placebo or the investigational product orally for 5 days. Patients will complete in-person and remote follow-up visits including assessments such as nasopharyngeal swabs, blood draws, and physical exams.

A study to evaluate the efficacy of Remdesivir in reducing the rate of all-cause medically attended visits or death in non-hospitalized participants with early stage COVID-19. To evaluate the safety of Remdesivir administered in an outpatient setting.

This research study is looking at experimental drugs to prevent the COVID-19 disease from occurring in people who have been exposed to the SARS-CoV-2 virus. The goals of the study is to see if REGN10933+REGN10987 lowers infection by the virus, whether they reduce the need for medical visits and the amount of time spent away from your day-to-day activities (i.e., work, school, caring for others) due to COVID-19, and whether they can cause side effects.

The purpose of this study is to evaluate the effect of tozorakimab as an add-on to SoC in patients with viral lung infection requiring supplemental oxygen on the prevention of death or progression to IMV/ECMO.

Meningococcal Group B Vaccine trial for teens, ages 16-18 years.

This phase III trial compares the usual treatment (treatment with ipilimumab and nivolumab followed by nivolumab alone) to treatment with ipilimumab and nivolumab, followed by nivolumab with cabozantinib in patients with untreated renal cell carcinoma that has spread to other parts of the body.